JP2011500650A5 - - Google Patents

Download PDF

Info

Publication number
JP2011500650A5
JP2011500650A5 JP2010529411A JP2010529411A JP2011500650A5 JP 2011500650 A5 JP2011500650 A5 JP 2011500650A5 JP 2010529411 A JP2010529411 A JP 2010529411A JP 2010529411 A JP2010529411 A JP 2010529411A JP 2011500650 A5 JP2011500650 A5 JP 2011500650A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
aplidine
cancer
gemcitabine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010529411A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011500650A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2008/064117 external-priority patent/WO2009050296A1/en
Publication of JP2011500650A publication Critical patent/JP2011500650A/ja
Publication of JP2011500650A5 publication Critical patent/JP2011500650A5/ja
Pending legal-status Critical Current

Links

JP2010529411A 2007-10-19 2008-10-20 改良された抗腫瘍治療 Pending JP2011500650A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98146307P 2007-10-19 2007-10-19
PCT/EP2008/064117 WO2009050296A1 (en) 2007-10-19 2008-10-20 Improved antitumoral treatments

Publications (2)

Publication Number Publication Date
JP2011500650A JP2011500650A (ja) 2011-01-06
JP2011500650A5 true JP2011500650A5 (OSRAM) 2011-12-08

Family

ID=40097474

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010529411A Pending JP2011500650A (ja) 2007-10-19 2008-10-20 改良された抗腫瘍治療

Country Status (6)

Country Link
US (1) US20100240595A1 (OSRAM)
EP (1) EP2205263A1 (OSRAM)
JP (1) JP2011500650A (OSRAM)
AU (1) AU2008313627A1 (OSRAM)
CA (1) CA2703024A1 (OSRAM)
WO (1) WO2009050296A1 (OSRAM)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE363910T1 (de) * 1999-11-15 2007-06-15 Pharma Mar Sa Behandlung von krebserkrankungen durch aplidin
RS54928B1 (sr) * 2006-02-28 2016-10-31 Pharma Mar Sa Poboljšano lečenje multiplog mijeloma
US20110009335A1 (en) * 2008-03-07 2011-01-13 Pharma Mar, S.A. Anticancer Treatments
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4950649A (en) * 1980-09-12 1990-08-21 University Of Illinois Didemnins and nordidemnins
US4493796A (en) * 1980-09-12 1985-01-15 Board Of Trustees, Univ. Of Ill. Didemnins A, B, C, and derivatives thereof, as antiviral agents
IT1153974B (it) * 1982-09-23 1987-01-21 Erba Farmitalia Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento
DE3684868D1 (de) * 1985-09-20 1992-05-21 Cernitin Sa Verwendung von pflanzenpollenextrakten zur herstellung von das wachstum von tumorzellen hemmenden pharmazeutischen praeparaten und verfahren zu ihrer herstellung.
US20030148933A1 (en) * 1990-10-01 2003-08-07 Pharma Mar S.A. Derivatives of dehydrodidemnin B
GB8922026D0 (en) * 1989-09-29 1989-11-15 Pharma Mar Sa Novel anti-viral and cytotoxic agent
US5580871A (en) * 1992-11-20 1996-12-03 The Dupont Merck Pharmaceutical Company 4-Heteroaryl- 1,4-dihydropyridine compounds with calcium agonist and alpha1 -antagonist activity
US5462726A (en) * 1993-12-17 1995-10-31 Bristol-Myers Squibb Company Method of inhibiting side effects of solvents containing ricinoleic acid or castor oil or derivatives thereof employing a thromboxane A2 receptor antagonist and pharmaceutical compositions containing such solvents
US6156724A (en) * 1996-06-07 2000-12-05 Rinehart; Kenneth L. Uses of didemnins as immunomodulating agents
US6034058A (en) * 1997-04-15 2000-03-07 Rinehart; Kenneth L. Semi-synthetic alanyl dilemnin analogs
JP4327260B2 (ja) * 1997-05-07 2009-09-09 フアルマ・マル・エセ・ア Ｌ型カルシウムチャンネルエンハンサーとしてのアプリジン
US6245759B1 (en) * 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
ATE363910T1 (de) * 1999-11-15 2007-06-15 Pharma Mar Sa Behandlung von krebserkrankungen durch aplidin
EP1276491B9 (en) * 2000-04-07 2007-02-28 The Trustees Of The University Of Pennsylvania Tamandarin and didemnin analogs and methods of making and using them
US6509315B1 (en) * 2000-04-07 2003-01-21 The Trustees Of The University Of Pennsylvania Didemnin analogs and fragments and methods of making and using them
UA76718C2 (uk) * 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
NZ525196A (en) * 2000-10-12 2004-09-24 Pharma Mar S Treatment of cancers by aplidine in conjunction with a myoprotector
WO2003033013A1 (en) * 2001-10-19 2003-04-24 Pharma Mar, S.A. Use of aplidine for the treatment of pancreatic cancer
UA83022C2 (uk) * 2003-03-12 2008-06-10 Фарма Мар, С.А. Аплідин для комбінованої терапії лейкозу та лімфоми
US7381703B2 (en) * 2003-03-12 2008-06-03 Dana-Faber Cancer Institute, Inc. Aplidine for multiple myeloma treatment
MXPA05010064A (es) * 2003-03-21 2006-05-17 Madeleine M Joullie Analogos de tamandarin y fragmentos de los mismos y metodos para hacerlos y usarlos.
RS54928B1 (sr) * 2006-02-28 2016-10-31 Pharma Mar Sa Poboljšano lečenje multiplog mijeloma

Similar Documents

Publication Publication Date Title
JP2015523397A5 (OSRAM)
JP2016528162A5 (OSRAM)
EA200901155A1 (ru) Модуляторы фармакокинетических свойств терапевтических препаратов (варианты) и их использование в терапии
BRPI0906181A2 (pt) "método para tratamento de uma disfunção hiperproliferativa, composição farmacêutica, uso de uma combinação terapêutica na fabricação de um medicamento para o tratamento de câncer, artigo de fabricação para tratamento de uma disfunção hiperproliferativa, método para determinação de compostos a serem usados em combinação para o tratamento de câncer e método para determinação de uma combinação terapêutica a ser usada para o tratamento de câncer"
JP2006504723A5 (OSRAM)
JP2010222367A5 (OSRAM)
JP2014532704A5 (OSRAM)
JP2011515481A5 (OSRAM)
HK1198869A1 (en) Combination treatments for hepatitis c
JP2015524444A5 (OSRAM)
BR112012003283A2 (pt) sal farmaceuticamente aceitável de um agente fotossensibilizante anfifílico, composição farmacêutica, produto, kit, uso de um sal farmaceuticamente aceitável de um agente fotossensibilizante anfifílico, e, método de introdução de uma molécula de medicamento no citosol de uma célula em um paciente.
JP2012517478A5 (OSRAM)
RU2015126661A (ru) Пероральная комбинация для предотвращения и лечения патологий мочевого пузыря, органов малого таза и мочеполового аппарата
JP2013518124A5 (OSRAM)
JP2006500346A5 (OSRAM)
NZ625592A (en) Compositions and methods for the treatment of hepatic diseases and disorders
RU2008152341A (ru) Применение аллопуринола для лечения ладонно-подошвенной эритродизестезии
JP2013541583A5 (OSRAM)
JP2015537009A5 (OSRAM)
JP2009515901A5 (OSRAM)
JP2009539994A5 (OSRAM)
JP2009506054A5 (OSRAM)
ATE543492T1 (de) Behandlung von lungenkrebs
JP2013544892A5 (OSRAM)
JP2015507020A5 (OSRAM)